To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.
The source supplies the latest action, but no lifecycle stage.
Latest action (7 Feb 2025): Referred to the House Committee on Energy and Commerce.
What this bill does
H.R. 1142 would amend the Public Health Service Act to require the Secretary of Health and Human Services to establish national drug adherence guidelines for medications covered under Medicare Part B and Part D. The stated goal of these guidelines is to achieve 90 percent patient adherence to prescribed drug regimens. In developing the guidelines, the Secretary would be directed to incorporate artificial intelligence and machine learning technologies and, where practicable, to promote the use of generic and biosimilar drugs rather than more expensive brand-name alternatives.
The bill primarily affects the Department of Health and Human Services, which would be tasked with creating and implementing these guidelines, as well as Medicare beneficiaries and the health care providers, pharmacies, and drug manufacturers involved in prescribing and dispensing Part B and D medications. The practical effects on patients, costs, or drug pricing are not specified in the bill text; it sets a policy goal and directs guideline development rather than establishing specific new programs, funding, or enforcement mechanisms.
The bill was introduced on February 7, 2025, by Rep. David Schweikert of Arizona and referred to the House Committee on Energy and Commerce. It has not yet been the subject of committee action, hearings, or a floor vote. As with most introduced bills, it would need to be approved by committee, pass the House and Senate, and be signed by the President to become law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish drug adherence guidelines for covered drugs under Medicare so as to achieve an adherence rate of 90%. The CMS must incorporate artificial intelligence and machine-learning technologies and promote generics and biosimilars when developing the guidance.
Timeline
7 Feb 2025
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 1142 do?
- H.R. 1142 would amend the Public Health Service Act to require the Secretary of Health and Human Services to establish national drug adherence guidelines for medications covered under Medicare Part B and Part D. The stated goal of these guidelines is to achieve 90 percent patient adherence to prescribed drug regimens. In developing the guidelines, the Secretary would be directed to incorporate artificial intelligence and machine learning technologies and, where practicable, to promote the use of generic and biosimilar drugs rather than more expensive brand-name alternatives. The bill primarily affects the Department of Health and Human Services, which would be tasked with creating and implementing these guidelines, as well as Medicare beneficiaries and the health care providers, pharmacies, and drug manufacturers involved in prescribing and dispensing Part B and D medications. The practical effects on patients, costs, or drug pricing are not specified in the bill text; it sets a policy goal and directs guideline development rather than establishing specific new programs, funding, or enforcement mechanisms. The bill was introduced on February 7, 2025, by Rep. David Schweikert of Arizona and referred to the House Committee on Energy and Commerce. It has not yet been the subject of committee action, hearings, or a floor vote. As with most introduced bills, it would need to be approved by committee, pass the House and Senate, and be signed by the President to become law.
- Has H.R. 1142 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 1142. Check the latest action and official source below.
- Who sponsored H.R. 1142?
- H.R. 1142 was sponsored by Rep. Schweikert, David [R-AZ-1] (R-AZ), with 0 cosponsors.
- What's the latest action on H.R. 1142?
- Referred to the House Committee on Energy and Commerce. (7 Feb 2025).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Schweikert, David [R-AZ-1]
SMARTER Act
Rural Broadband Modernization Act
Advancing American Innovation Act
AIDEN (Advancing Integrated Data for Equitable National Child Welfare)
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.